The Semax research compound is a synthetic heptapeptide analog of adrenocorticotropic hormone fragment ACTH(4-10) developed for laboratory investigation into neurotrophic factor regulation and central nervous system stress responses. In preclinical models, Semax is primarily evaluated for its ability to modulate brain-derived neurotrophic factor (BDNF) signaling pathways and neuroprotective molecular cascades.
The Semax research compound is a synthetic heptapeptide analog of adrenocorticotropic hormone fragment ACTH(4-10) developed for laboratory investigation into neurotrophic factor regulation and central nervous system stress responses. In preclinical models, Semax is primarily evaluated for its ability to modulate brain-derived neurotrophic factor (BDNF) signaling pathways and neuroprotective molecular cascades.
The Semax research compound is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MW: 873.97 g/mol). Structurally derived from the N-terminal sequence of endogenous adrenocorticotropic hormone—specifically the regulatory fragment ACTH(4-10)—Semax incorporates a tripeptide C-terminal extension consisting of Proline-Glycine-Proline (Pro-Gly-Pro). This specific enzymatic stabilization sequence protects the molecule against rapidly acting central and peripheral peptidases, significantly extending its structural half-life during in vitro and ex vivo experimentation.
Unlike native hormonal peptides derived from pro-opiomelanocortin (POMC), Semax lacks hormonal or steroidogenic activity because it omits the C-terminal sequence necessary for systemic adrenal stimulation. Consequently, researchers utilizing high-purity Semax in laboratory assays can isolate central signal transduction effects—such as neurotrophin synthesis—without confounding systemic glucocorticoid elevation. Laboratory investigators interested in peptide kinetics frequently evaluate this modified sequence when studying peptide stability and degradation across varying physiological media.
Preclinical literature indicates that the Semax research compound exerts its cellular actions primarily through modulation of neurotrophic factors and melanocortin receptor systems. Pharmacological assays demonstrate that Semax functions as a low-affinity agonist at melanocortin MC4 and MC5 receptors. Rather than inducing classical G-protein signaling downstream of these receptors, the peptide appears to modulate endogenous ligand binding and downstream gene expression.
In vitro gene expression profiling reveals that exposure to Semax rapidly upregulates the transcription of brain-derived neurotrophic factor (BDNF) and its primary signal-transducing receptor, tropomyosin receptor kinase B (TrkB), within mammalian hippocampal and cortical neuronal cultures. Additional mechanisms documented in our peptide research hub show that Semax stimulates nerve growth factor (NGF) mRNA expression and influences local neurovascular coupling by modulating nitric oxide synthase (NOS) isoform activity.
Investigative studies utilizing rodent models of cerebral ischemia and acute excitotoxicity demonstrate marked shifts in transcriptomic and proteomic profiles following Semax administration. In rodent hippocampal slice preparations, the peptide has been shown to preserve synaptic transmission efficiency under oxygen-glucose deprivation (OGD) conditions. This neuroprotective effect correlates with sustained BDNF expression and suppressed apoptotic marker activity, including caspase-3 cleavage.
Furthermore, rodent behavioral and electrophysiological data suggest that Semax-mediated upregulation of BDNF pathways enhances long-term potentiation (LTP) in the CA1 region of the hippocampus. Researchers investigating BDNF-pathway peptides observe that the kinetics of neurotrophic induction by Semax occur rapidly—often within 1 to 3 hours post-exposure in cell culture—and persist longer than those observed with native, unmodified ACTH fragments.
Beyond its direct action on neuronal primary cultures, the Semax research compound exhibits regulatory effects on cerebrovascular endothelial cells and glial populations. In primary microglial and astrocyte cell cultures subjected to lipopolysaccharide (LPS) challenge, treatment with Semax attenuates the expression of pro-inflammatory cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
Concurrently, preclinical studies suggest that Semax influences the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) under hypoxic conditions. This dual action—attenuating neuroinflammatory cascade signaling while promoting localized angiogenic factor release—makes Semax a frequent candidate in laboratory models assessing cellular resilience against ischemia, oxidative stress, and metabolic deprivation.
To contextualize the signaling profile of the Semax research compound within neurobiology research, laboratory investigators frequently compare it against other regulatory peptides and synthetic analogs. The table below outlines key biochemical differences observed in preclinical literature:
When designing comparative study protocols, researchers often benchmark Semax against Selank, a synthetic heptapeptide derived from the endogenous immunomodulator tuftsin. While Semax targets BDNF synthesis and melanocortin signaling, Selank operates primarily through GABAergic modulation and enkephalin degradation inhibition. Investigators evaluating broader neuroprotective profiles may also include Epithalon for telomerase expression assays, or compare non-peptide mechanisms using research articles on Noopept mechanisms. Each compound offers distinct receptor specificity and metabolic pathways for comparative in vitro modeling.
The Semax research compound is supplied as a lyophilized (freeze-dried) cake or powder requiring reconstitution prior to in vitro experimental use. To maintain structural integrity and prevent aggregation, aseptic technique must be maintained throughout handling.
Standard laboratory reconstitution protocols utilize sterile, preservative-free Bacteriostatic Water (0.9% benzyl alcohol) or sterile Phosphate-Buffered Saline (PBS, pH 7.4). Solvents should be added down the inner glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl mixing is recommended; vortexing or aggressive mechanical agitation should be avoided to prevent shear-induced peptide denaturing. For step-by-step dilution calculations and molarity adjustments, investigators can consult our reconstitution calculator guide.
Lyophilized Semax demonstrates high stability when stored at sub-zero temperatures. For long-term preservation, intact vials should be stored at -20°C or -80°C in a desiccated environment protected from direct light exposure. Under these conditions, the lyophilized peptide remains stable for up to 24 months.
Once reconstituted into aqueous solution, Semax is susceptible to hydrolytic cleavage and peptide bond degradation over extended timeframes. Reconstituted stock solutions prepared in sterile PBS or bacteriostatic water should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles and stored at 2°C to 8°C for short-term assays (up to 30 days) or -20°C for extended storage (up to 3 months).
To ensure reproducible experimental outcomes, research institutions must source the Semax research compound from verified vendors utilizing rigorous analytical validation. Inconsistent purity or undetected endotoxin contamination can invalidate cell culture viability assays and generate false transcriptomic data.
At PX1 Research, every lot of Semax is USA-manufactured in GMP-compliant facilities and undergoes mandatory batch testing through an independent ISO 17025 accredited laboratory. Analytical testing includes reverse-phase high-performance liquid chromatography (RP-HPLC) to verify chromatographic purity exceeds 98.0%, mass spectrometry (MS) to confirm exact molecular weight (873.97 g/mol), and Chromogenic LAL assays to guarantee endotoxin levels remain below 0.01 EU/mg. Batch-specific Certificates of Analysis (COAs) are publicly accessible for every lot. Qualified academic and corporate research facilities can also establish institutional accounts via our wholesale portal or browse our complete catalog of all peptides.
What is the structural classification of the Semax research compound?
Semax is a synthetic heptapeptide derived from the N-terminal sequence of adrenocorticotropic hormone (ACTH 4-10) with a C-terminal Proline-Glycine-Proline (Pro-Gly-Pro) tripeptide extension, yielding the sequence Met-Glu-His-Phe-Pro-Gly-Pro.
How does the C-terminal Pro-Gly-Pro motif affect Semax stability?
The Pro-Gly-Pro extension inhibits rapid cleavage by endogenous carboxypeptidases and aminopeptidases, significantly extending the peptide's metabolic stability in biological matrices compared to native ACTH(4-10).
What neurotrophic factors are modulated by Semax in preclinical assays?
Preclinical studies demonstrate that Semax upregulates transcript levels and protein expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), as well as their corresponding receptor TrkB, in neuronal tissue cultures.
What analytical methods are required to verify the quality of Semax?
High-purity Semax requires verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity, Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular identity, and Limulus Amebocyte Lysate (LAL) testing for bacterial endotoxins.
What reconstituted storage protocol preserves Semax integrity?
Reconstituted Semax solutions should be aliquoted into single-use microtubes to avoid freeze-thaw degradation and stored at 2°C to 8°C for short-term work (up to 30 days) or -20°C for up to 90 days.
Does Semax exhibit systemic glucocorticoid or hormonal activity in assays?
No. Because Semax lacks the full sequence of native ACTH required for adrenal receptor activation, it does not stimulate corticosterone or cortisol release in experimental models.
What are PX1 Research's endotoxin standards for Semax?
PX1 Research requires all peptide lots, including Semax, to pass LAL endotoxin testing showing levels strictly below 0.01 EU/mg to prevent cellular activation or cytotoxicity in laboratory assays.
Is the Semax research compound approved for human administration?
No. The Semax research compound supplied by PX1 Research is strictly sold for laboratory research, in vitro experimentation, and preclinical scientific study. It is not for human or animal consumption, medical treatment, or clinical use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.